The introduction of nicotinamide for a nicotine substitution in e-cigarette and smokeless products represents a significant regulatory obstacle for that FDA. Nicotinamide does not have nicotinic receptor agonist exercise and is understood to work as a sedative at substantial dosages6. The promises created by Nicotine River, ECBlend, and other vendo